Keywords: chiron, ends, rhigf-1, clinical, development, osteoarthritis, poor
Chiron ends rhIGF-1 clinical development in osteoarthritis on poor Phase IIa
Article | 26 July 2000
Chiron Corp says that it has terminated clinical development of itsrecombinant human insulin-like growth factor-1 product in osteoarthritis, following disappointing ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
